We published a revision to our Precision Medicine Scorecard: Drug Company Edition last month. As John Audette rightfully notes, there are multiple factors in a pharmaceutical company’s contribution to precision medicines: How many precision medicines a company...
We’ve been curious about Celgene’s activity in precision medicine for some time. We’ve posted blog posts here, here and here proposing that Celgene’s activities are indicative of a precision medicine push. As a supplement, this weeks CotW is...
Trends in biomarker types and uses, test development, and drug enablement are described in this new report, along with a breakdown of the companies that are doing the most to advance precision medicine. 10:00 ET from Amplion Inc. BEND, Ore., May 4, 2016 /PRNewswire/...
Personalized medicine is an exciting space that is moving and changing quickly. Staying on top of the changes and identifying parallel opportunities is difficult. How do you identify what disease areas are complementary to your existing product strategy? What is...
At Amplion we have a commercial interest in access to high quality clinical information that can inform and contribute to our flagship product, BiomarkerBase. However, we are truly passionate about contributing to higher quality, more personalized, medical...
